Abstract
Over the past 10–15 years a substantial body of harmonizing pharmaceutical legislation has been adopted by all constituent countries of the European Union. This has facilitated the creation of a common, European-wide system for the authorization and subsequent supervision of medicinal products. Central to this was the creation of the European Agency for the Evaluation of Medicinal Products (the European Medicines Evaluation Agency, EMEA). The EMEA, which became operational in February 1995, is charged with managing and coordinating the new drug approval system within the European Union. This new approval system provides for the evaluation of any new product marketing application via one of two routes; a “centralized” route mandatory for all products of biotechnology, and a “decentralized” route. Despite the inevitable teething problems, the EMEA has proven itself efficient. Within its first three years of operation, it has facilitated the granting of 52 European-wide marketing authorizations, of which 23 were products of biotechnology. By and large, the EMEA has now gained the confidence of both the European pharmaceutical industry and the various national regulatory authorities within each EU member state.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
http://europa.eu.int(Internet home page of Europa, the European Union’s server).
The rules governing medicinal products in the European Union, Volumes 1–9. 1998 ed. European Commission, Directorate General I II ( Industry, Pharmaceuticals and Cosmetics ).
Jeffries, D. & Jones, K. (1995) EMEA and the new pharmaceutical procedures for Europe. Eur. J. Clin. Pharmacol. 47, 471–476.
Sauer, F. (1997) A new and fast drug approval system in Europe. Drug Inform. J. 31, 1–6.
http://www.eudra.org/emea.html(Internet home page of the EMEA).
http://www.eudra.org/home.html(Internet home page of network services for the European Union Pharmaceutical Regulatory sector).
The European agency for the evaluation of medicinal products. First, second and third general reports (1995, 1996 and 1997, respectively). Office for Official Publications of the European Communities, L-2985, Luxembourg.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Walsh, G. (1999). The EMEA and regulatory control of (bio)pharmaceuticals within the European Union. In: Walsh, G., Murphy, B. (eds) Biopharmaceuticals, an Industrial Perspective. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-0926-2_12
Download citation
DOI: https://doi.org/10.1007/978-94-017-0926-2_12
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-5237-7
Online ISBN: 978-94-017-0926-2
eBook Packages: Springer Book Archive